Erratum to: Bone sialoprotein deficiency impairs osteoclastogenesis and mineral resorption in vitro (Journal of Bone and Mineral Research, (2010), 25, 12, (2669-2679), 10.1002/jbmr.245);Bone sialoprotein deficiency impairs osteoclastogenesis and mineral resorption in vitro

Journal of Bone and Mineral Research

Volumn 25, Issue 12, 2010, Pages 2669-2679

  Boudiffa, Maya ^a,b,d   Wade Gueye, Ndéye Marième ^a,b,d   Guignandon, Alain ^a,b,d   Vanden Bossche, Arnaud ^a,b,d   Sabido, Odile ^a,c,d   Aubin, Jane E ^e   Jurdic, Pierre ^f   Vico, Laurence ^a,b,d   Lafage Proust, Marie Hélène ^a,b,d   Malaval, Luc ^a,b,d  

^a UNIVERSITÉ DE LYON   (France)

^b INSERM   (France)

^c Lab de Biochim   (France)

^d UNIVERSITÉ JEAN MONNET   (France)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITÉ DE LYON   (France)

Author keywords

BSP; Osteoclast; Resorption; Sibling

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BONE SIALOPROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE SIALOPROTEIN DEFICIENCY; CELL ADHESION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; ENZYME BLOOD LEVEL; GENE EXPRESSION; MINERAL METABOLISM; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOCLASTOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; SPLEEN CELL;

EID: 78649623144     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.4094     Document Type: Erratum

References (34)

1. Rodan GA, Martin TJ., Therapeutic approaches to bone diseases. Science. 2000; 289: 1508-1514.
2. Sodek J, Ganss B, McKee MD., Osteopontin. Crit Rev Oral Biol Med. 2000; 11: 279-303.
3. Ganss B, Kim RH, Sodek J., Bone sialoprotein. Crit Rev Oral Biol Med. 1999; 10: 79-98.
4. Bianco P, Fisher LW, Young MF, Termine JD, Robey PG., Expression of bone sialoprotein (BSP) in developing human tissues. Calcif Tissue Int. 1991; 49: 421-426.
5. Arai N, Ohya K, Kasugai S, et al. Expression of bone sialoprotein mRNA during bone formation and resorption induced by colchicine in rat tibial bone marrow cavity. J Bone Miner Res. 1995; 10: 1209-1217.
6. Valverde P, Zhang J, Fix A, et al. Overexpression of bone sialoprotein leads to an uncoupling of bone formation and bone resorption in mice. J Bone Miner Res. 2008; 23: 1775-1788.
7. Tu Q, Zhang J, Fix A, et al. Targeted overexpression of BSP in osteoclasts promotes bone metastasis of breast cancer cells. J Cell Physiol. 2009; 218: 135-145.
8. Fisher LW, Fedarko NS., Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res. 2003; 44 (Suppl 1): 33-40.
9. Ross FP, Chappel J, Alvarez JI, et al. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem. 1993; 268: 9901-9907.
10. Chellaiah MA, Kizer N, Biswas R, et al. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell. 2003; 14: 173-189.
11. Malaval L, Wade-Gueye NM, Boudiffa M, et al. Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. J Exp Med. 2008; 205: 1145-1153.
12. Raynal C, Delmas PD, Chenu C., Bone sialoprotein stimulates in vitro bone resorption. Endocrinology. 1996; 137: 2347-2354.
13. Valverde P, Tu Q, Chen J., BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. J Bone Miner Res. 2005; 20: 1669-1679.
14. Nagy A, Rossant J, Nagy R, Abramow-Newerly W, Roder JC., Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc Natl Acad Sci U S A. 1993; 90: 8424-8428.
15. Miyamoto T, Arai F, Ohneda O, Takagi K, Anderson DM, Suda T., An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand. Blood. 2000; 96: 4335-4343.
16. Rittling SR, Matsumoto HN, McKee MD, et al. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res. 1998; 13: 1101-1111.
17. Arai F, Miyamoto T, Ohneda O, et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med. 1999; 190: 1741-1754.
18. Lomaga MA, Yeh WC, Sarosi I, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 1999; 13: 1015-1024.
19. Grigoriadis AE, Wang ZQ, Cecchini MG, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science. 1994; 266: 443-448.
20. Franzoso G, Carlson L, Xing L, et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev. 1997; 11: 3482-3496.
21. Kim K, Kim JH, Lee J, et al. Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem. 2005; 280: 35209-35216.
22. Asagiri M, Sato K, Usami T, et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med. 2005; 202: 1261-1269.
23. Sakai H, Chen Y, Itokawa T, Yu KP, Zhu ML, Insogna K., Activated c-Fms recruits Vav and Rac during CSF-1-induced cytoskeletal remodeling and spreading in osteoclasts. Bone. 2006; 39: 1290-1301.
24. Faccio R, Takeshita S, Zallone A, Ross FP, Teitelbaum SL., c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin Invest. 2003; 111: 749-758.
25. Asagiri M, Takayanagi H., The molecular understanding of osteoclast differentiation. Bone. 2007; 40: 251-264.
26. Nakamura I, Tanaka H, Rodan GA, Duong LT., Echistatin inhibits the migration of murine prefusion osteoclasts and the formation of multinucleated osteoclast-like cells. Endocrinology. 1998; 139: 5182-5193.
27. Suzuki K, Zhu B, Rittling SR, et al. Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts. J Bone Miner Res. 2002; 17: 1486-1497.
28. Hershey CL, Fisher DE., Mitf and Tfe3: members of a b-HLH-ZIP transcription factor family essential for osteoclast development and function. Bone. 2004; 34: 689-696.
29. Miyamoto T., The dendritic cell-specific transmembrane protein DC-STAMP is essential for osteoclast fusion and osteoclast bone-resorbing activity. Mod Rheumatol. 2006; 16: 341-342.
30. Lee SH, Rho J, Jeong D, et al. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med. 2006; 12: 1403-1409.
31. Kim K, Lee SH, Ha Kim J, Choi Y, Kim N., NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol. 2008; 22: 176-185.
32. Qin C, Baba O, Butler WT., Post-translational modifications of sibling proteins and their roles in osteogenesis and dentinogenesis. Crit Rev Oral Biol Med. 2004; 15: 126-136.
33. Pfaff M, Jurdic P., Podosomes in osteoclast-like cells: structural analysis and cooperative roles of paxillin, proline-rich tyrosine kinase 2 (Pyk2) and integrin alphaVbeta3. J Cell Sci. 2001; 114 (Pt 15): 2775-2786.
34. Nakamura I, Pilkington MF, Lakkakorpi PT, et al. Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone. J Cell Sci. 1999; 112 (Pt 22): 3985-3993.